Compounded and brand-name GLP-1 medications: key differences
They are not the same product and they do not follow the same regulatory path. This comparison separates what is known about approved brand drugs from what must be evaluated for an individual compounded preparation.
Side-by-side comparison
| Topic | FDA-approved brand drug | Compounded preparation |
|---|---|---|
| FDA status | The finished product was reviewed and approved for specific indications. | It is not FDA-approved and is not brand-identical. |
| Clinical evidence | Trials apply to the studied product, dose, and formulation. | Brand-trial results cannot be transferred as an effectiveness promise. |
| How it reaches a patient | A licensed pharmacy dispenses the prescribed product. | If applicable requirements are met, a licensed pharmacy prepares and dispenses a prescription for an identified patient. |
| Availability | Depends on indication, prescription, coverage, and inventory. | Depends on medical need, prescription, legal requirements, location, and pharmacy capacity. |
| Cost | Varies by product, dose, coverage, and manufacturer program. | Varies by prescription and pharmacy. The $119 medical review is separate from medication cost. |
What the 503A pathway means
Section 503A sets conditions for certain preparations made by a licensed pharmacy for an identified patient based on a valid prescription. Meeting those conditions does not make a compounded preparation FDA-approved.
For a copy of a commercially available drug, federal law limits compounding regularly or in inordinate amounts. A significant difference must be based on the individual patient's need and determined by the prescriber. Cost or a general formulation preference alone should not be presented as an automatic justification.
How to evaluate an option without assuming equivalence
- 1. Confirm the indication.
Ask which diagnosis and individual medical need guide the recommendation. - 2. Confirm the pharmacy.
Verify its active state license and public disciplinary history. - 3. Confirm the cost.
Get the evaluation fee, separate medication price, and follow-up charges in writing.
Primary sources
Confirm availability first
If care is available for your location, the medical review is $119. Medication is priced separately, and a prescription is never guaranteed.
Check availabilityFrequently asked questions
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Wegovy and Ozempic are FDA-approved finished products. Compounded semaglutide is not FDA-approved, is not brand-identical, and results vary by individual.
Does brand-drug trial evidence predict the result of a compounded preparation?
No. A trial supports the product, dose, and formulation that were studied. Its results should not be presented as evidence of effectiveness for a different compounded preparation.
Who prepares and dispenses a 503A preparation?
If prescribed, the licensed pharmacy prepares and dispenses the prescription for the identified patient. The clinic performs the medical evaluation but does not manufacture or dispense the medication.
When may a compounded preparation be considered?
FDA states that a compounded drug may be appropriate when a patient's medical need cannot be met by an available approved drug. The prescriber and dispensing pharmacy are responsible for the applicable decision and documentation.
What does the $119 medical review cover?
The $119 fee covers the medical evaluation and, if approved, the prescribing decision. Medication is priced separately. Availability depends on location, clinical evaluation, and a pharmacy able to dispense legally.
This content is educational and does not replace a medical evaluation. No outcome is guaranteed. Do not start, stop, or change a medication without speaking with your health care professional.